Clincosm LogoSign in Get a demo

ALK-Positive Anaplastic Large Cell Lymphoma

Showing 1 - 6 of 6
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma

Active, not recruiting
  • ALK-Positive Anaplastic Large Cell Lymphoma
  • RNAseq
  • Toulouse, France
    IUCT-Oncopole University Hospital
Jul 3, 2023

Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

Completed
Has Results
  • Peripheral T Cell Lymphoma
  • +18 more
  • Vancouver, British Columbia, Canada
  • +29 more
Apr 29, 2022

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Toripalimab,

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • Toripalimab, Rituximab
  • R-CHOP Protocol
  • Guangzhou, Guangdong, China
    Department of hematology department, Nanfang hospital
Apr 6, 2022

Non-GCB/ABC DLBCL, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (PD-1 Antibody, Lenalidomide)

Recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • +5 more
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Mar 12, 2021

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Camrelizumab,

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Mar 10, 2021

ALK-Positive Anaplastic Large Cell Lymphoma Trial in Zhengzhou (Crizotinib, Etoposide Capsule, Auto-HSCT)

Unknown status
  • ALK-Positive Anaplastic Large Cell Lymphoma
  • Zhengzhou, Henan, China
    Oncology Department of The First Affiliated Hospital of Zhengzho
Oct 12, 2018